Skip Navigation


JAC Advance Access originally published online on January 28, 2008
Journal of Antimicrobial Chemotherapy 2008 61(3):755-757; doi:10.1093/jac/dkn005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/3/755    most recent
dkn005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ballester, F.
Right arrow Articles by Guarro, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ballester, F.
Right arrow Articles by Guarro, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus

Frederic Ballester1,2, F.Javier Pastor1 and Josep Guarro1,*

1 Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain 2 Hospital Universitari de Sant Joan, Reus, Spain

* Corresponding author. Tel: +34-977-759359; Fax: +34-977-759322; E-mail: josep.guarro@urv.cat

Keywords: zygomycosis , itraconazole , Rhizopus oryzae , Rhizopus microsporus var. rhizopodiformis

The first 10% of the full text of this article appears below.

Sir,

Zygomycosis is a severe, life-threatening fungal infection that occurs mainly in patients with diabetes mellitus, or with haematological malignancies, after organ transplantation, in conditions of iron overload or those treated with immunosuppressive drugs. Rhizopus oryzae, followed by Rhizopus microsporus var. rhizopodiformis, are the most frequently involved organisms, accounting for ~75% of all cases. Amphotericin B is the drug of choice for the treatment of zygomycosis, but overall mortality rate is high. Recently, posaconazole has shown to be active . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?